Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)-Reference-Cited by-同舟云学术

Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)

Published:2022-07-14 Issue:10 Volume:57 Page:1556-1563
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Maffini Enrico,Labopin Myriam^ORCID,Beelen Dietrich Wilhelm^ORCID,Kroeger Nicolaus^ORCID,Arat Mutlu^ORCID,Wilson Keith M. O.,Bay Jacques-Olivier,Ganser Arnold,Martin Hans,Passweg Jakob,Kottaridis Panagiotis D.,Yakoub-Agha Ibrahim^ORCID,Porras Rocio Parody,Wagner Eva Maria,Esteve Jordi^ORCID,Lanza Francesco^ORCID,Nagler Arnon^ORCID,Mohty Mohamad^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-022-01748-w.pdf

Reference63 articles.

1. Brüggemann M, Raff T, Flohr T, Gokbuget N, Nakao M, Droese J, et al. German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116–23.

2. Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113:4153–62.

3. Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14:199–209.

4. Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020;6:1890–9.

5. Kohlmann A, Nadarajah N, Alpermann T, Grossmann V, Schindela S, Dicker f, et al. Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease. Leukemia. 2014;1:129–37.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel insights and therapeutic approaches in secondary AML;Frontiers in Oncology;2024-07-29

2. Monitoring molecular changes in the management of myelodysplastic syndromes;British Journal of Haematology;2024-06-27

3. Prognostic Role and Clinical Utility of Measurable Residual Disease in Acute Myeloid Leukemia;Advances in Oncology;2024-05

4. Test then erase? Current status and future opportunities for Measurable Residual Disease testing in Acute Myeloid Leukemia;Acta Haematologica;2023-11-30

5. CNT and Graphene-Based Transistor Biosensors for Cancer Detection: A Review;Biomolecules;2023-06-22